Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Eli Lilly announced that its next-generation weight loss drug, retatrutide, successfully passed a late-stage trial for obesity treatment. The drug demonstrated significant weight loss results, with some patients losing over 28% of their body weight. This development positions Lilly to seek approval for retatrutide, which could become a key player in the competitive weight loss drug market.
- ▪Retatrutide helped patients lose an average of 28.3% of their weight over 80 weeks.
- ▪Approximately 45% of participants in the trial achieved 30% or more weight loss.
- ▪The drug is expected to generate significant sales, potentially reaching $3.8 billion by 2030.
Opening excerpt (first ~120 words) tap to expand
Eli Lilly on Thursday said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing for approval of the weekly injection, called retatrutide, which works differently from existing shots and pills from both Lilly and Novo Nordisk. It also appears to be more effective than those options.The highest dose of retatrutide helped patients lose 28.3% of their weight — or 70.3 pounds — on average over 80 weeks, compared to 2.2% with placebo, when evaluating only patients who stayed on the drug.Roughly 45% of the 2,500 patients in the Phase 3 trial achieved 30% or more weight loss, Lilly said.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at US Top News and Analysis.
Discussion
0 commentsMore from US Top News and Analysis
